Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Akebia Therapeutics (NASDAQ: AKBA ) is currently working on kidney-related diseases, mostly by using its HIF platform. As it stands now, AKBA is transitioning from relying on Auryxia to Vafseo, which is probably the biggest risk it faces today. Nevertheless, Vafseo is seeing some early successes soMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio Univer ...